{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.1","upperLimit":"49.3","value":"3.4"},{"groupId":"OG001","lowerLimit":"0.9","upperLimit":"24.3","value":"1.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"144"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"description":"Time to increased hemoglobin, defined as the time from randomization to at least one category improvement from Baseline in common terminology criteria for adverse events (CTCAE) grade for hemoglobin level. Hemoglobin categories are: 1) Normal; 2) CTCAE Grade 1: \\< lower limit of normal (LLN) to 10.0 g/dL; 3) CTCAE Grade 2: \\< 10.0 to \\<8.0 g/dL. Participants with CTCAE Grade 3 anemia or worse at Baseline were excluded from the study.","dispersionType":"Full Range","groups":[{"description":"Participants received 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle and 40 mg dexamethasone (participants \\> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression.","id":"OG000","title":"Pomalidomide Plus Low-Dose Dexamethasone"},{"description":"Participants received 40 mg dexamethasone (participants \\> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1 through 4, 9 through 12, and 17 through 20 of a 28-day cycle until disease progression.","id":"OG001","title":"High-Dose Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat population with improvement in hemoglobin during the study","reportingStatus":"POSTED","timeFrame":"From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.","title":"Time to the First Hemoglobin Improvement","type":"SECONDARY","unitOfMeasure":"weeks"}